OBJECTIVE: To evaluate changes in neuropsychological (NP) performance and in plasma and cell surface markers of peripheral monocyte activation/migration after treatment with cenicriviroc (CVC), a dual C-C chemokine receptor type 2 (CCR2) and type 5 (CCR5) antagonist, in treatment-experienced, HIV-infected individuals. SETTING: Single-arm, 24-week, open-label clinical trial. METHODS:HIV-infected individuals on antiretroviral therapy ≥1 year with plasma HIV RNA ≤50 copies per milliliter and below-normal cognitive performance [defined as age-, sex-, and education-adjusted NP performance (NPZ) <-0.5 in a single cognitive domain or in global performance] were enrolled. Changes over 24 weeks were assessed for global and domain-specific NPZ scores, plasma markers of monocyte/macrophage activation [neopterin, soluble (s)CD14, and sCD163] quantified by ELISA, and CCR2 and CCR5 expression on monocytes, and T cells measured by flow cytometry. RESULTS:Seventeen of 20 enrolled participants completed the study. Improvements over 24 weeks were observed in global NPZ [median change (Δ) = 0.24; P = 0.008], and in cognitive domains of attention (Δ0.23; P = 0.011) and working memory (Δ0.44; P = 0.017). Plasma levels of sCD163, sCD14 and neopterin decreased significantly (P's < 0.01). CCR2 and CCR5 monocyte expression remained unchanged; however, CCR5 levels on CD4 and CD8 T cells and CCR2 expression on CD4 T cells increased (P's < 0.01). CONCLUSIONS:CVC given over 24 weeks was associated with improved NP test performance and decreased plasma markers of monocyte immune activation in virally suppressed, HIV-infected participants. These data potentially link changes in monocyte activation to cognitive performance. Further study of CVC for HIV cognitive impairment in a randomized controlled study is warranted.
RCT Entities:
OBJECTIVE: To evaluate changes in neuropsychological (NP) performance and in plasma and cell surface markers of peripheral monocyte activation/migration after treatment with cenicriviroc (CVC), a dual C-C chemokine receptor type 2 (CCR2) and type 5 (CCR5) antagonist, in treatment-experienced, HIV-infected individuals. SETTING: Single-arm, 24-week, open-label clinical trial. METHODS:HIV-infected individuals on antiretroviral therapy ≥1 year with plasma HIV RNA ≤50 copies per milliliter and below-normal cognitive performance [defined as age-, sex-, and education-adjusted NP performance (NPZ) <-0.5 in a single cognitive domain or in global performance] were enrolled. Changes over 24 weeks were assessed for global and domain-specific NPZ scores, plasma markers of monocyte/macrophage activation [neopterin, soluble (s)CD14, and sCD163] quantified by ELISA, and CCR2 and CCR5 expression on monocytes, and T cells measured by flow cytometry. RESULTS: Seventeen of 20 enrolled participants completed the study. Improvements over 24 weeks were observed in global NPZ [median change (Δ) = 0.24; P = 0.008], and in cognitive domains of attention (Δ0.23; P = 0.011) and working memory (Δ0.44; P = 0.017). Plasma levels of sCD163, sCD14 and neopterin decreased significantly (P's < 0.01). CCR2 and CCR5 monocyte expression remained unchanged; however, CCR5 levels on CD4 and CD8 T cells and CCR2 expression on CD4 T cells increased (P's < 0.01). CONCLUSIONS:CVC given over 24 weeks was associated with improved NP test performance and decreased plasma markers of monocyte immune activation in virally suppressed, HIV-infectedparticipants. These data potentially link changes in monocyte activation to cognitive performance. Further study of CVC for HIV cognitive impairment in a randomized controlled study is warranted.
Authors: Lehn K Weaver; Katharine A Hintz-Goldstein; Patricia A Pioli; Kathleen Wardwell; Nilofer Qureshi; Stefanie N Vogel; Paul M Guyre Journal: J Leukoc Biol Date: 2006-07 Impact factor: 4.962
Authors: Eliseo A Eugenin; Kristin Osiecki; Lillie Lopez; Harris Goldstein; Tina M Calderon; Joan W Berman Journal: J Neurosci Date: 2006-01-25 Impact factor: 6.167
Authors: Ian Kusao; Bruce Shiramizu; Chin-Yuan Liang; John Grove; Melissa Agsalda; David Troelstrup; Van-Nicholas Velasco; Andrew Marshall; Nicholas Whitenack; Cecilia Shikuma; Victor Valcour Journal: J Neuropsychiatry Clin Neurosci Date: 2012 Impact factor: 2.198
Authors: Dionna W Williams; Tina M Calderon; Lillie Lopez; Loreto Carvallo-Torres; Peter J Gaskill; Eliseo A Eugenin; Susan Morgello; Joan W Berman Journal: PLoS One Date: 2013-07-26 Impact factor: 3.240
Authors: Marie-Josée Brouillette; Tracy Yuen; Lesley K Fellows; Lucette A Cysique; Robert K Heaton; Nancy E Mayo Journal: PLoS One Date: 2016-05-18 Impact factor: 3.240
Authors: Thomas A Premeaux; Michelle L D'Antoni; Mohamed Abdel-Mohsen; Satish K Pillai; Kalpana J Kallianpur; Beau K Nakamoto; Melissa Agsalda-Garcia; Bruce Shiramizu; Cecilia M Shikuma; Magnus Gisslén; Richard W Price; Victor Valcour; Lishomwa C Ndhlovu Journal: J Neurovirol Date: 2018-11-26 Impact factor: 2.643
Authors: P Lorenzo Bozzelli; Tao Yin; Valeria Avdoshina; Italo Mocchetti; Katherine E Conant; Kathleen A Maguire-Zeiss Journal: Glia Date: 2019-05-23 Impact factor: 7.452
Authors: Michelle L D'Antoni; Brooks I Mitchell; Sara McCurdy; Mary Margaret Byron; Debra Ogata-Arakaki; Dominic Chow; Nehal N Mehta; William A Boisvert; Eric Lefebvre; Cecilia M Shikuma; Lishomwa C Ndhlovu; Yvonne Baumer Journal: J Leukoc Biol Date: 2018-08-08 Impact factor: 4.962